血清可溶性 CD163 与多发性肌炎和皮肌炎的相关性，尤其是在抗 MDA5 抗体阳性病例中。
Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
机构信息
From the Institute of Rheumatology, Tokyo Women's Medical University; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.
H. Kawasumi, MD, Institute of Rheumatology, Tokyo Women's Medical University; Y. Katsumata, MD, PhD, Institute of Rheumatology, Tokyo Women's Medical University; N. Nishino, MD, Institute of Rheumatology, Tokyo Women's Medical University; S. Hirahara, MD, Institute of Rheumatology, Tokyo Women's Medical University; Y. Kawaguchi, MD, PhD, Institute of Rheumatology, Tokyo Women's Medical University; M. Kuwana, MD, PhD, Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine; H. Yamanaka, MD, PhD, Institute of Rheumatology, Tokyo Women's Medical University.
出版信息
J Rheumatol. 2018 Jul;45(7):947-955. doi: 10.3899/jrheum.170997. Epub 2018 Apr 15.
OBJECTIVE
We elucidated the association of serum soluble CD163 (sCD163) with rapidly progressive interstitial lung disease (RP-ILD), autoantibody profiles, and serum ferritin in patients with polymyositis (PM), classic dermatomyositis (DM), and clinical amyopathic dermatomyositis (CADM).
METHODS
Serum sCD163 levels were retrospectively measured by ELISA in patients with PM, classic DM, and CADM, as well as in healthy controls (HC). Repeat sera samples were obtained posttreatment from available patients. The associations between serum sCD163 levels and clinical information were analyzed.
RESULTS
Serum sCD163 levels in patients with PM/classic DM/CADM were significantly higher than those in HC (n = 72, 56, 34, and 68, respectively; p < 0.001 for all comparisons). No significant difference was observed between serum sCD163 levels in patients with and without ILD (p = 0.16) or between those with RP-ILD and chronic ILD (p = 0.21). Serum sCD163 levels were significantly higher in patients with anti-MDA5 antibodies (n = 27) than in those without (p = 0.001). Serum sCD163 levels were weakly correlated with serum ferritin levels in the patients with PM, classic DM, and CADM (r = 0.21). Serum sCD163 levels decreased significantly following treatment in all patient groups (p = 0.003).
CONCLUSION
The present results suggest an association of serum sCD163 with PM, classic DM, and CADM, especially in anti-MDA5 antibody-positive cases. However, serum sCD163 levels were not specifically associated with ILD or RP-ILD.
目的
本研究旨在阐明血清可溶性 CD163（sCD163）与多发性肌炎（PM）、经典皮肌炎（DM）和临床无肌病性皮肌炎（CADM）患者中快速进展性间质性肺病（RP-ILD）、自身抗体谱和血清铁蛋白之间的关系。
方法
通过酶联免疫吸附试验（ELISA）回顾性检测 PM、经典 DM 和 CADM 患者及健康对照者（HC）血清 sCD163 水平。对可获得的患者进行治疗后重复采集血清样本。分析血清 sCD163 水平与临床资料的相关性。
结果
PM/经典 DM/CADM 患者血清 sCD163 水平明显高于 HC（n = 72、56、34 和 68，p < 0.001）。ILD 患者与无 ILD 患者之间（p = 0.16）或 RP-ILD 患者与慢性 ILD 患者之间（p = 0.21）血清 sCD163 水平无显著差异。抗 MDA5 抗体阳性（n = 27）患者血清 sCD163 水平明显高于无抗 MDA5 抗体患者（p = 0.001）。PM、经典 DM 和 CADM 患者血清 sCD163 水平与血清铁蛋白水平呈弱相关（r = 0.21）。所有患者组治疗后血清 sCD163 水平均显著降低（p = 0.003）。
结论
本研究结果提示血清 sCD163 与 PM、经典 DM 和 CADM 相关，尤其是抗 MDA5 抗体阳性病例。然而，血清 sCD163 水平与 ILD 或 RP-ILD 无特异性相关性。
Zotero 插件